{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:09:15Z","timestamp":1762866555728,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,2]],"date-time":"2015-01-02T00:00:00Z","timestamp":1420156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013993","name":"Theravance Biopharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013993","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.diagmicrobio.2014.12.011","type":"journal-article","created":{"date-parts":[[2014,12,31]],"date-time":"2014-12-31T02:02:00Z","timestamp":1419991320000},"page":"275-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method"],"prefix":"10.1016","volume":"81","author":[{"given":"Rodrigo E.","family":"Mendes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Streit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0085","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1128\/AAC.01513-07","article-title":"Effect of polysorbate 80 on oritavancin binding to plastic surfaces: Implications for susceptibility testing","volume":"52","author":"Arhin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0060","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1345\/aph.1Q331","article-title":"Successful treatment of polymicrobial calcaneal osteomyelitis with telavancin, rifampin, and meropenem","volume":"46","author":"Brinkman","year":"2012","journal-title":"Ann Pharmacother"},{"year":"2012","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M07-A9","author":"Clinical and Laboratory Standards Institute (CLSI)","key":"10.1016\/j.diagmicrobio.2014.12.011_bb0125"},{"year":"2013","series-title":"Performance standards for antimicrobial susceptibility testing: 23rd Informational Supplement M100-S23","author":"Clinical and Laboratory Standards Institute (CLSI)","key":"10.1016\/j.diagmicrobio.2014.12.011_bb0100"},{"year":"2014","series-title":"Performance standards for antimicrobial susceptibility testing: 24th Informational Supplement M100-S24","author":"Clinical and Laboratory Standards Institute (CLSI)","key":"10.1016\/j.diagmicrobio.2014.12.011_bb0090"},{"author":"Clinigen Healthcare Ltd","key":"10.1016\/j.diagmicrobio.2014.12.011_bb0015"},{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0040","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1128\/AAC.00062-10","article-title":"Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model","volume":"54","author":"Crandon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0050","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1128\/AAC.01101-08","article-title":"Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits","volume":"53","author":"Darouiche","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"author":"EUCAST","key":"10.1016\/j.diagmicrobio.2014.12.011_bb0140"},{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0095","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1128\/AAC.03172-14","article-title":"Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies","volume":"58","author":"Farrell","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"author":"Health Canada","key":"10.1016\/j.diagmicrobio.2014.12.011_bb0010"},{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0045","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/jac\/dkq028","article-title":"Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia","volume":"65","author":"Hegde","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0075","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/jac\/dkr234","article-title":"Successful treatment of methicillin-resistant Staphylococcus aureus mitral valve endocarditis with sequential linezolid and telavancin monotherapy following daptomycin failure","volume":"55","author":"Joson","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0030","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.diagmicrobio.2010.10.031","article-title":"In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007\u20132009 study","volume":"69","author":"Karlowsky","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0065","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/jac\/dks165","article-title":"Successful treatment of methicillin-resistant Staphylococcus epidermidis prosthetic joint infection with telavancin","volume":"67","author":"Kaushal","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0115","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.00301-10","article-title":"In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates","volume":"54","author":"Mendes","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.diagmicrobio.2011.05.012","article-title":"Update on the telavancin activity tested against European staphylococcal clinical isolates (2009\u20132010)","volume":"71","author":"Mendes","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.diagmicrobio.2011.09.023","article-title":"Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA hospitals (2007\u20132009)","volume":"72","author":"Mendes","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0105","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1128\/AAC.00011-12","article-title":"Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents","volume":"56","author":"Mendes","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0110","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.diagmicrobio.2010.03.009","article-title":"Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results","volume":"67","author":"Putnam","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0080","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1128\/JCM.02411-06","article-title":"Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent","volume":"45","author":"Rennie","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0055","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jac\/dkl222","article-title":"Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus","volume":"58","author":"Reyes","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0120","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1128\/JCM.01210-14","article-title":"Quality control MIC ranges for telavancin when applying a revised CLSI reference broth microdilution method","volume":"52","author":"Ross","year":"2014","journal-title":"J Clin Microbiol"},{"author":"Theravance Biopharma Antibiotics, Inc","key":"10.1016\/j.diagmicrobio.2014.12.011_bb0135"},{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0070","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1093\/jac\/dkr329","article-title":"Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis","volume":"66","author":"Twilla","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.12.011_bb0035","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1128\/AAC.00922-12","article-title":"Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus","volume":"56","author":"Xiong","year":"2012","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889314005215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889314005215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:51:29Z","timestamp":1760003489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889314005215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0732889314005215"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2014.12.011","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2014.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}